Third, it has now been recognized that M2 macrophages can be therapeutically exploited to treat obesity [45], but additional studies would be necessary to translate our current discoveries into clinical settings, particularly for the development of Kdm2a inhibitors with minimal side effect. The gene discussed is KDM2A; the disease is obesity due to melanocortin 4 receptor deficiency.